NA Brain Cancer Diagnostic Market - Industry Trends and Forecast to 2030

Description

List of Tables

North America brain cancer diagnostic market is projected to register a substantial CAGR of 19.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

North America Brain Cancer Diagnostic Market, By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography (EEG), and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21,21-34, 35-65, and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others), Country ( U.S., Canada, and Mexico), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America brain cancer diagnostic market are:

Rising cases of brain cancer worldwide

Rising awareness of early diagnosis of brain cancer

Improved imaging techniques

Innovations in drug delivery to brain cancer cells

Market Players

Some of the key market players for the North America brain cancer diagnostic market are listed below:

NIHON KOHDEN CORPORATION.

FUJIFILM Holdings Corporation

GE HealthCare

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Canon Inc.

Others

1 INTRODUCTION 24

1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26

2 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 29

2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.6 MULTIVARIATE MODELLING 36
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 36
2.8 DBMR MARKET POSITION GRID 37
2.9 VENDOR SHARE ANALYSIS 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 SECONDARY SOURCES 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 44

4.1 PESTEL ANALYSIS 45
4.2 PORTER'S FIVE FORCES 46

5 EPIDEMIOLOGY 47

6 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 48

7 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 49

7.1 REGULATORY SCENARIO IN THE U.S 49
7.2 REGULATORY SCENARIO IN AUSTRALIA 50
7.3 REGULATORY SCENARIO IN JAPAN 50
7.4 REGULATORY SCENARIO IN CHINA 50

8 MARKET OVERVIEW 52

8.1 DRIVERS 54
- 8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 54
- 8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 54
- 8.1.3 IMPROVED IMAGING TECHNIQUES 55
- 8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 55
8.2 RESTRAINTS 56
- 8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 56
- 8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 56
- 8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 57
8.3 OPPORTUNITIES 57
- 8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 57
- 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 57
- 8.3.3 RISING HEALTHCARE EXPENDITURE 58
8.4 CHALLENGES 59
- 8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 59
- 8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 59

9 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 60

9.1 OVERVIEW 61
9.2 IMAGING TEST 64
- 9.2.1 CT SCAN 65
- 9.2.2 MRI 65
- 9.2.3 PET 65
- 9.2.4 OTHERS 65
9.3 MOLECULAR TESTING 66
9.4 ELECTROENCEPHALOGRAPHY (EEG) 66
9.5 LUMBAR PUNCTURE 67
9.6 BIOPSY 68
- 9.6.1 OPEN BIOPSY 69
- 9.6.2 STEREOTACTIC BIOPSY 69
- 9.6.3 NEEDLE BIOPSY 69
- 9.6.4 NEUROENDOSCOPY 69
9.7 OTHERS 69

10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 70

10.1 OVERVIEW 71
10.2 GLIOBLASTOMA MULTIFORME 74
10.3 MENINGIOMAS 75
10.4 ASTROCYTOMAS 76
10.5 ACOUSTIC NEUROMA 77
10.6 OLIGODENDROGLIOMA 78
10.7 OLIGODENDROGLIOMA 78
10.8 OTHERS 79

11 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 80

11.1 OVERVIEW 81
11.2 35-65 84
11.3 65 AND ABOVE 85
11.4 BELOW 21 86
11.5 21-34 87

12 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 88

12.1 OVERVIEW 89
12.2 HOSPITALS 92
12.3 SPECIALTY CLINICS 93
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 94
12.5 AMBULATORY SURGICAL CENTERS 95
12.6 OTHERS 96

13 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 97

13.1 NORTH AMERICA 98
- 13.1.1 U.S. 105
- 13.1.2 CANADA 107
- 13.1.3 MEXICO 109

14 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 111

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111

15 SWOT ANALYSIS 112

16 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 113

16.1 KONINKLIJKE PHILIPS N.V. 113
- 16.1.1 COMPANY SNAPSHOT 113
- 16.1.2 REVENUE ANALYSIS 113
- 16.1.3 COMPANY SHARE ANALYSIS 114
- 16.1.4 PRODUCT PORTFOLIO 114
- 16.1.5 RECENT DEVELOPMENTS 115
16.2 CANON INC. 116
- 16.2.1 COMPANY SNAPSHOT 116
- 16.2.2 REVENUE ANALYSIS 116
- 16.2.3 COMPANY SHARE ANALYSIS 117
- 16.2.4 PRODUCT PORTFOLIO 117
- 16.2.5 RECENT DEVELOPMENT 117
16.3 SIEMENS HEALTHCARE GMBH 118
- 16.3.1 COMPANY SNAPSHOT 118
- 16.3.2 REVENUE ANALYSIS 119
- 16.3.3 COMPANY SHARE ANALYSIS 119
- 16.3.4 PRODUCT PORTFOLIO 120
- 16.3.5 RECENT DEVELOPMENTS 120
16.4 BD 121
- 16.4.1 COMPANY SNAPSHOT 121
- 16.4.2 REVENUE ANALYSIS 122
- 16.4.3 COMPANY SHARE ANALYSIS 122
- 16.4.4 PRODUCT PORTFOLIO 123
- 16.4.5 RECENT DEVELOPMENTS 123
16.5 NIHON KOHDEN CORPORATION. 124
- 16.5.1 COMPANY SNAPSHOT 124
- 16.5.2 RECENT FINANCIALS 124
- 16.5.3 COMPANY SHARE ANALYSIS 125
- 16.5.4 PRODUCT PORTFOLIO 125
- 16.5.5 RECENT DEVELOPMENT 125
16.6 BIOCEPT, INC. 126
- 16.6.1 COMPANY SNAPSHOT 126
- 16.6.2 REVENUE ANALYSIS 126
- 16.6.3 PRODUCT PORTFOLIO 127
- 16.6.4 RECENT DEVELOPMENT 127
16.7 BIOMIND 128
- 16.7.1 COMPANY SNAPSHOT 128
- 16.7.2 PRODUCT PORTFOLIO 128
- 16.7.3 RECENT DEVELOPMENT 128
16.8 CEREBRAL DIAGNOSTIC 129
- 16.8.1 COMPANY SNAPSHOT 129
- 16.8.2 PRODUCT PORTFOLIO 129
- 16.8.3 RECENT DEVELOPMENT 129
16.9 DXCOVER LIMITED 130
- 16.9.1 COMPANY SNAPSHOT 130
- 16.9.2 PRODUCT PORTFOLIO 130
- 16.9.3 RECENT DEVELOPMENT 130
16.10 FONAR CORP. 131
- 16.10.1 COMPANY SNAPSHOT 131
- 16.10.2 REVENUE ANALYSIS 131
- 16.10.3 PRODUCT PORTFOLIO 132
- 16.10.4 RECENT DEVELOPMENT 132
16.11 FUJIFILM CORPORATION 133
- 16.11.1 COMPANY SNAPSHOT 133
- 16.11.2 REVENUE ANALYSIS 133
- 16.11.3 PRODUCT PORTFOLIO 134
- 16.11.4 RECENT DEVELOPMENT 134
16.12 GE HEALTHCARE. 135
- 16.12.1 COMPANY SNAPSHOT 135
- 16.12.2 REVENUE ANALYSIS 135
- 16.12.3 PRODUCT PORTFOLIO 136
- 16.12.4 RECENT DEVELOPMENT 136
16.13 HITACHI, LTD. 137
- 16.13.1 COMPANY SNAPSHOT 137
- 16.13.2 REVENUE ANALYSIS 137
- 16.13.3 PRODUCT PORTFOLIO 138
- 16.13.4 RECENT DEVELOPMENT 138
16.14 MINFOUND MEDICAL SYSTEMS CO., 139
- 16.14.1 COMPANY SNAPSHOT 139
- 16.14.2 PRODUCT PORTFOLIO 139
- 16.14.3 RECENT DEVELOPMENT 139
16.15 NANTOMICS. 140
- 16.15.1 COMPANY SNAPSHOT 140
- 16.15.2 PRODUCT PORTFOLIO 140
- 16.15.3 RECENT DEVELOPMENT 140
16.16 NEUSOFT CORPORATION 141
- 16.16.1 COMPANY SNAPSHOT 141
- 16.16.2 REVENUE ANALYSIS 141
- 16.16.3 PRODUCT PORTFOLIO 142
- 16.16.4 RECENT DEVELOPMENT 142
16.17 SEQUOIA HEALTHCARE. 143
- 16.17.1 COMPANY SNAPSHOT 143
- 16.17.2 PRODUCT PORTFOLIO 143
- 16.17.3 RECENT DEVELOPMENT 143
16.18 STERNMED GMBH 144
- 16.18.1 COMPANY SNAPSHOT 144
- 16.18.2 PRODUCT PORTFOLIO 144
- 16.18.3 RECENT DEVELOPMENT 144
16.19 THERMO FISHER SCIENTIFIC INC. 145
- 16.19.1 COMPANY SNAPSHOT 145
- 16.19.2 REVENUE ANALYSIS 145
- 16.19.3 PRODUCT PORTFOLIO 146
- 16.19.4 RECENT DEVELOPMENT 146
16.20 TIME MEDICAL HOLDING. 147
- 16.20.1 COMPANY SNAPSHOT 147
- 16.20.2 PRODUCT PORTFOLIO 147
- 16.20.3 RECENT DEVELOPMENTS 147

17 QUESTIONNAIRE 148

18 RELATED REPORTS 151

LIST OF TABLES

TABLE 1 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 54
TABLE 2 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 3 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 56
TABLE 4 NORTH AMERICA MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 57
TABLE 5 NORTH AMERICA ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 6 NORTH AMERICA LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 7 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 8 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 59
TABLE 9 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 64
TABLE 11 NORTH AMERICA GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 12 NORTH AMERICA MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 13 NORTH AMERICA ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 14 NORTH AMERICA ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 15 NORTH AMERICA OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 16 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 17 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 74
TABLE 18 NORTH AMERICA 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 19 NORTH AMERICA 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 20 NORTH AMERICA BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 21 NORTH AMERICA 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 78
TABLE 22 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 82
TABLE 23 NORTH AMERICA HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 25 NORTH AMERICA DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 26 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 27 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 28 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 93
TABLE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 93
TABLE 30 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 93
TABLE 31 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
TABLE 32 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 94
TABLE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 94
TABLE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 95
TABLE 35 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 36 U.S. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 37 U.S. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 38 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 97
TABLE 39 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 97
TABLE 40 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 97
TABLE 41 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 42 CANADA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 43 CANADA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 44 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 99
TABLE 45 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 99
TABLE 46 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 99
TABLE 47 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 48 MEXICO IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 49 MEXICO BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 50 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 101
TABLE 51 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 101
TABLE 52 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 101

LIST OF FIGURES

FIGURE 1 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 19
FIGURE 2 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 22
FIGURE 3 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 23
FIGURE 4 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 24
FIGURE 5 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 24
FIGURE 6 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 25
FIGURE 7 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID 27
FIGURE 8 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 29
FIGURE 9 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID 30
FIGURE 10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 33
FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 34
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 34
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET 43
FIGURE 14 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022 51
FIGURE 15 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION) 52
FIGURE 16 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 52
FIGURE 17 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 53
FIGURE 18 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022 61
FIGURE 19 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION) 62
FIGURE 20 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030) 62
FIGURE 21 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE 63
FIGURE 22 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022 71
FIGURE 23 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 72
FIGURE 24 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030) 72
FIGURE 25 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE 73
FIGURE 26 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022 79
FIGURE 27 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 80
FIGURE 28 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 80
FIGURE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 81
FIGURE 30 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 89
FIGURE 31 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 90
FIGURE 32 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 90
FIGURE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 91
FIGURE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 91
FIGURE 35 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 101